Lipid Profiling Workflow Demonstrates Disrupted Lipogenesis Induced with Drug Treatment in Leukemia Cells

Using an Agilent 6546 LC/Q-TOF and MassHunter Lipid Annotator Software

contributed by Agilent Technologies | 02/17/2021

Abstract

The Agilent lipidomics profiling workflow, using the Agilent 6546 LC/Q-TOF and Agilent MassHunter Lipid Annotator software, was applied to the study of drug‑treated acute myeloid leukemia (AML) cells. The results confirmed previously reported observations, and revealed lipid differences made evident through the expanded coverage of this comprehensive workflow.

Log in or register to read this article in full and gain access to The Analytical Scientist’s entire content archive. It’s FREE!

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

Receive communication from The Cannabis Scientist I want to stay up to date with the Mass Spectrometry field I want to stay up to date with the Spectroscopy field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.